# Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

> **NCT04626791** · PHASE2 · RECRUITING · sponsor: **Academic and Community Cancer Research United** · enrollment: 45 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Rituximab and Hyaluronidase Human

## Key facts

- **NCT ID:** NCT04626791
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-03
- **Primary completion:** 2024-08-03
- **Final completion:** 2028-08-03
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626791, "Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04626791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*